One of the burning questions at present is whether utilizing a dual SGLT1/2 inhibitor like Sotagliflozin (SOTA) may be more beneficial than sole SGLT2i’s such as EMPA, CANA or DAPA when it comes to the treatment of cardiorenal disease in both patients with and without diabetes. This evidence concerns the gene SLC5A1 and diabetes mellitus.